Cendakimab vs Dupilumab in EoE — PatSnap Eureka
Cendakimab vs. Dupilumab in Eosinophilic Esophagitis: Oral IL-33 Receptor Antagonist Phase III Landscape
The IL-33/ST2 signaling axis has emerged as a compelling upstream therapeutic target in eosinophilic esophagitis. Explore how cendakimab's oral small-molecule mechanism positions against dupilumab's approved IL-4Rα pathway in this growing unmet medical need.
EoE: A Chronic Antigen-Driven Inflammatory Disease With Growing Unmet Need
Eosinophilic esophagitis (EoE) is a chronic, antigen-driven inflammatory disease of the esophagus characterized by eosinophilic infiltration and type 2 immune activation. The condition represents a significant and growing unmet medical need in both pediatric and adult populations, with diagnosis rates rising steadily across North America, Europe, and Asia-Pacific regions. According to PubMed/MEDLINE, EoE prevalence is estimated at 1–5 per 10,000 individuals in Western populations.
The IL-33/ST2 signaling axis has emerged as a compelling upstream therapeutic target in allergic and eosinophilic disease. IL-33, released by epithelial cells in response to antigen exposure, signals through the ST2 receptor to trigger downstream type 2 cytokine release — including IL-4, IL-5, and IL-13 — ultimately driving eosinophil recruitment to the esophageal mucosa. Blocking this upstream node with agents like cendakimab may suppress a broader effector cascade than downstream pathway inhibitors.
Dupilumab, approved by the FDA for EoE in adults and adolescents, targets the IL-4Rα receptor subunit shared by IL-4 and IL-13 signaling. Its approval established a clinical proof-of-concept for biologic intervention in EoE, but the subcutaneous injection route and biologic manufacturing complexity create differentiation opportunities for oral small-molecule alternatives. The PatSnap life sciences intelligence platform tracks over 2 billion data points across global drug pipelines and patent filings relevant to this therapeutic area.
Cendakimab — also referenced in clinical and patent literature as RPC4046 and ABT-308 — is an oral small-molecule antagonist of the ST2 receptor currently in Phase III development. Its oral bioavailability positions it as a potentially differentiated approach versus approved IL-4Rα/IL-13 pathway inhibitors, particularly for patient populations with injection fatigue or pediatric dosing requirements where oral formulation flexibility is valuable. Researchers can explore the full IP landscape via PatSnap Analytics.
Cendakimab vs. Dupilumab: Mechanism and Clinical Development Comparison
A structured comparison of the IL-33/ST2 and IL-4Rα therapeutic approaches in eosinophilic esophagitis across mechanism, modality, and clinical trial design dimensions.
Therapeutic Target Dimension Comparison
Cendakimab's upstream IL-33/ST2 blockade versus dupilumab's downstream IL-4Rα inhibition across five mechanistic axes relevant to EoE.
Head-to-Head: Key Development Metrics
Direct comparison of molecule class, administration route, target, clinical stage, and primary EoE endpoints between cendakimab and dupilumab.
Type 2 Inflammatory Cascade in EoE: Where Each Agent Intervenes
IL-33 initiates the upstream type 2 cascade via ST2, driving IL-4, IL-5, and IL-13 release, ultimately causing eosinophilic infiltration. Cendakimab intercepts at ST2; dupilumab intercepts at IL-4Rα.
What a Complete Cendakimab IP Analysis Requires
A comprehensive IP landscape for the cendakimab vs. dupilumab EoE competitive space spans five distinct data dimensions — each requiring targeted patent and literature retrieval.
Chemical Structure & Oral Formulation Patents
Patent filings from AstraZeneca or licensee partners covering cendakimab's chemical structure, formulation as an oral small molecule, and ST2 antagonism mechanism of action are the foundational IP layer. Oral bioavailability strategies and dosing regimen claims are particularly relevant to freedom-to-operate analysis. The European Patent Office Espacenet database is a key source for these filings.
RPC4046 · ABT-308 · ST2 antagonismPhase II/III Clinical Trial Design & EoE Endpoints
Clinical literature describing Phase II/III trial designs in EoE, including primary endpoints such as peak eosinophil count per high-power field (eos/hpf) and Dysphagia Symptom Questionnaire (DSQ) scores, patient stratification criteria, and safety outcomes are essential for efficacy benchmarking. ClinicalTrials.gov maintains the authoritative registry for ongoing EoE Phase III studies.
Peak eos/hpf · DSQ score · Safety outcomesComparative & Network Meta-Analysis: IL-33 vs IL-4Rα
Comparative or network meta-analysis papers evaluating dupilumab (IL-4Rα antagonist) versus IL-33/ST2 pathway agents in eosinophilic disease are critical for positioning cendakimab's clinical differentiation. These studies typically synthesize histologic and symptomatic response rates across trials to enable indirect treatment comparisons where head-to-head data is not yet available. PatSnap Analytics enables automated landscape synthesis across these literature sources.
Network meta-analysis · Indirect comparison · EoE biologicsPediatric Formulation & Regulatory Pathway IP
IP landscape filings covering oral bioavailability strategies, dosing regimens, and pediatric formulation patents are increasingly important as EoE affects both adult and pediatric populations. Regulatory and translational documents referencing IND submissions, Breakthrough Therapy designations, or FDA guidance for EoE endpoints complete the picture. PatSnap's Trust Center outlines how proprietary IP data is handled securely for enterprise research teams.
Pediatric dosing · Breakthrough Therapy · FDA EoE guidanceRecommended Search & Database Strategy for Cendakimab Intelligence
When primary patent database searches return insufficient records, a structured multi-database approach ensures comprehensive coverage of the cendakimab and EoE competitive landscape.
Cendakimab vs. Dupilumab in EoE — Key Questions Answered
Cendakimab is an oral small-molecule IL-33/ST2 receptor antagonist targeting the upstream IL-33 signaling axis in eosinophilic esophagitis, whereas dupilumab is an injectable IL-4Rα biologic antagonist that blocks IL-4 and IL-13 signaling. The oral bioavailability of cendakimab represents a potential differentiation versus dupilumab's subcutaneous administration route.
The IL-33/ST2 signaling axis is an upstream driver of type 2 immune activation and eosinophilic infiltration in allergic and eosinophilic diseases including eosinophilic esophagitis. Because IL-33 acts upstream of IL-4, IL-5, and IL-13, blocking the ST2 receptor may offer broader suppression of the type 2 inflammatory cascade compared with downstream pathway inhibitors.
Key primary endpoints in EoE clinical trials include peak eosinophil count per high-power field (eos/hpf) on esophageal biopsy and Dysphagia Symptom Questionnaire (DSQ) scores. Patient stratification criteria and safety outcomes are also central to Phase II and III trial designs in this indication.
Cendakimab is also referenced in patent and clinical literature under the synonyms RPC4046 and ABT-308. Searches using these identifiers, alongside terms such as ST2 antagonist, IL1RL1, and EoE Phase III, are recommended when querying patent databases, ClinicalTrials.gov, and PubMed/MEDLINE.
Recommended databases for cendakimab IP research include ClinicalTrials.gov, the European Patent Register (Espacenet), PubMed/MEDLINE, the USPTO full-text patent database, and proprietary pipeline databases such as Cortellis, Citeline Pharmaprojects, and Evaluate Pharma. PatSnap Eureka provides AI-powered patent and literature search across these and additional global sources.
The most relevant IP dimensions for the cendakimab EoE competitive landscape include patent filings covering cendakimab's chemical structure and oral small-molecule formulation, ST2 antagonism mechanism of action, oral bioavailability strategies, dosing regimens, pediatric formulation patents, and regulatory documents referencing IND submissions, Breakthrough Therapy designations, or FDA guidance for EoE endpoints.
Still have questions about cendakimab, IL-33 antagonism, or the EoE drug landscape? Let PatSnap Eureka answer them for you.
Ask Eureka Your EoE Research QuestionAccelerate Your EoE Drug Intelligence Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D across pharma, biotech, and life sciences IP landscapes.
References
- ClinicalTrials.gov — National Library of Medicine EoE Phase III Trial Registry
- PubMed/MEDLINE — National Center for Biotechnology Information: EoE Prevalence and IL-33 Pathway Literature
- European Patent Office (EPO) Espacenet — ST2 Antagonist and Oral Formulation Patent Filings
- U.S. Food and Drug Administration (FDA) — Dupilumab EoE Approval and Guidance for EoE Endpoints
- PatSnap — Innovation Intelligence Platform: Life Sciences IP and Pipeline Analytics
- PatSnap Life Sciences Solutions — Drug Discovery and EoE Pipeline Intelligence
- PatSnap Analytics — Patent Landscape Analysis for Biologics and Small Molecules
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Pathway biology descriptions are derived from published literature. No clinical trial outcome data is fabricated or estimated.
PatSnap Eureka searches patents and research to answer instantly.